37404-22-1

Basic information

• Product Name: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-, ethyl ester
• CAS NO: 37404-22-1
• Molecular Formula: C12H15IO3
• Molecular Weight: 334.154
• Mol File: 37404-22-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-, ethyl ester(37404-22-1)
• EPA Substance Registry System: Propanoic acid, 2-(4-iodophenoxy)-2-methyl-, ethyl ester(37404-22-1)

Safety Data

• Hazardous Substances Data: 37404-22-1(Hazardous Substances Data)

Upstream product

• 600-00-0 ethyl 2-bromoisobutyrate 
• 540-38-5 p-Iodophenol 
• 37404-23-2 2-(4-iodophenoxy)-2-methylpropanoic acid 

Downstream Products

• 37404-23-2 2-(4-iodophenoxy)-2-methylpropanoic acid 

Relevant articles and documents

Catalytic Enantio- And Diastereoselective Cyclopropanation of 2-Azadienes for the Synthesis of Aminocyclopropanes Bearing Quaternary Carbon Stereogenic Centers

We report the catalytic enantio- and diastereoselective preparation of aminocyclopropanes by the cyclopropanation of terminal and (Z)-internal 2-azadienes with donor/acceptor carbenes derived from α-diazoesters. The resulting cyclopropanes bear quaternary carbon stereogenic centers vicinal to the amino-substituted carbon and are formed as a single diastereomer in up to 99:1 er and 97% yield with 0.5 mol % of Rh2(DOSP)4 and only 1.5 equiv of the diazo reagent. Transformations with internal azadienes afford cyclopropanes with three contiguous stereogenic centers.

Treatment of skin conditions by use of PPAR alpha activators

Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor alpha , and oxysterol activators of the LXR alpha receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.